IRLAB Therapeutics AB Class A (6IRA) Price & Analysis

Compare

1 Followers

6IRA Stock Chart & Stats

€0.18

-€0.01(-1.25%)

At close: Jan 08 4:00 PM EST

€0.18

-€0.01(-1.25%)

Day’s Range― - ―

52-Week Range€0.15 - €1.27

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€14.20M

Enterprise Value€64.95M

Total Cash (Recent Filing)€110.13M

Total Debt (Recent Filing)€29.81M

Price to Earnings (P/E)―

Beta-0.15

Next Earnings

Feb 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding84,858,246

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)17.09

Price to Sales (P/S)5.89

P/FCF Ratio-8.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth / Pipeline MomentumSustained ~13% TTM revenue growth after a prior step-change suggests durable pipeline or partnering momentum. For a clinical-stage biotech, rising revenue signals progressing partnerships or milestones that can provide recurring non-product cash inflows and validate program advancement over months.

Improved Leverage Reduces Balance-sheet RiskA marked fall in debt-to-equity to ~0.55 materially lowers refinancing and solvency risk versus 2024. This improvement extends runway flexibility for R&D spending, reduces interest burden and supports funding of clinical programs over the medium term without immediate distress.

Partnering-based Business ModelA business model focused on licensing, milestone payments and royalties lets the company monetize R&D without building broad commercial infrastructure. Structurally this reduces fixed-cost scale needs and provides potential non-dilutive cash at defined program milestones over the coming quarters.

Bears Say

Substantial Cash Burn And Negative FCFPersistently negative operating and free cash flow indicate ongoing funding reliance. Even with improvement versus 2024, continued burn makes the company dependent on external financing or milestone receipts, increasing dilution risk and constraining multi-program development plans.

Negative Gross Profit And Large Operating LossesNegative gross profit and sustained operating losses show the business remains far from breakeven. For a development-stage biotech this implies continued capital consumption to fund trials, limiting ability to self-fund growth and weakening bargaining power with partners and investors over time.

Equity Erosion And Deeply Negative ROEMaterial equity decline and deeply negative ROE reflect capital consumption and likely dilution. This undermines long-term shareholder value, makes future equity raises more costly and signals persistent inability to generate positive returns from invested capital absent a material change in operations or milestones.

IRLAB Therapeutics AB Class A News

IRLAB to Webcast Year-End 2025 Results as Parkinson’s Pipeline Advances

An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics AB, a...

1d ago

IRLAB partners with Denmark’s Biomia to apply AI-driven ISP platform to CNS drug candidates

An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics has entered...

1M ago

IRLAB Wins Green Light for Phase Ib Trial of Novel Apathy Drug in Parkinson’s

IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has provided an announcement. IRLAB Therapeutics has obtained regulatory and...

2M ago

IRLAB Secures New Patent for Mesdopetam, Strengthening Market Position

The latest announcement is out from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ). IRLAB Therapeutics AB announced...

2M ago

IRLAB to Present at Redeye Technology & Life Science Day 2025

An announcement from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics AB announced...

3M ago

IRLAB Therapeutics Appoints Nomination Committee for 2026 AGM

An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics AB has...

3M ago

IRLAB’s Research Advances Highlighted at AD/PD 2026 Conference

IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has issued an announcement. IRLAB Therapeutics announced the acceptance of...

3M ago

IRLAB Therapeutics Advances Drug Development with New Funding and Patent

IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has shared an update. IRLAB Therapeutics AB’s interim report for...

4M ago

IRLAB Therapeutics to Present Q3 2025 Interim Report via Webcast

IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) just unveiled an update. IRLAB Therapeutics AB announced a presentation...

4M ago

IRLAB Therapeutics Appoints New CFO to Strengthen Leadership

The latest announcement is out from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ). IRLAB Therapeutics has appointed...

4M ago

6IRA FAQ

What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?

IRLAB Therapeutics AB Class A lowest stock price was €0.15 and its highest was €1.27 in the past 12 months.

What is IRLAB Therapeutics AB Class A’s market cap?

IRLAB Therapeutics AB Class A’s market cap is €14.20M.

When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?

IRLAB Therapeutics AB Class A’s upcoming earnings report date is Feb 25, 2026 which is in 6 days.

How were IRLAB Therapeutics AB Class A’s earnings last quarter?

IRLAB Therapeutics AB Class A released its earnings results on Oct 29, 2025. The company reported -€0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.022.

Is IRLAB Therapeutics AB Class A overvalued?

According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does IRLAB Therapeutics AB Class A pay dividends?

IRLAB Therapeutics AB Class A does not currently pay dividends.

What is IRLAB Therapeutics AB Class A’s EPS estimate?

IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does IRLAB Therapeutics AB Class A have?

IRLAB Therapeutics AB Class A has 84,858,246 shares outstanding.

What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?

IRLAB Therapeutics AB Class A reported an EPS of -€0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.756%.

Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?

Currently, no hedge funds are holding shares in DE:6IRA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

IRLAB Therapeutics AB Class A

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.